Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20439751 | 0.73 | GRM2 (0.53) | GRM2SLC9A1HCAR3POLB | |
| SCHEMBL17828279 | 0.73 | GRM2 (0.67) | GRM2SLC9A1NPC1 | |
| SCHEMBL8737413 | 0.72 | SLC9A1 (0.34) | SLC9A1CLK1DYRK1ANPC1LMNA | |
| SCHEMBL18323572 | 0.71 | GRM2 (0.42) | GRM2SLC9A1CLK1DYRK1AHCAR3 | |
| SCHEMBL24375502 | 0.69 | GRM2 (0.45) | GRM2SLC9A1HCAR3ADORA2AADORA2B | |
| SCHEMBL10525877 | 0.65 | KMT2A (0.45) | GRM2SLC9A1POLBALDH1A1LMNA | |
| SCHEMBL4083654 | 0.64 | GRM2 (0.47) | GRM2NPC1 | |
| SCHEMBL18323583 | 0.64 | ADORA2A (0.41) | ADORA2AADORA2BALDH1A1 | |
| SCHEMBL18803136 | 0.64 | GRM2 (0.50) | GRM2SLC9A1 | |
| SCHEMBL18803135 | 0.64 | GRM2 (0.46) | GRM2SLC9A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |